Abstract: An object of the present invention is to provide a method for stabilizing a substance DFP-11207 sensitive to humidity and unstable at high humidity, and a stabilized preparation thereof, and more specifically, provide a capsule preparation for treating cancer, containing DFP-11207 or a pharmaceutically acceptable salt thereof and a hygroscopic agent.

Abstract: An object of the present invention is to provide a highly effective method for treatment/remission of cancer, and prevention of recurrence/metastasis of cancer at low cost and with few side effects. A composition containing a urinary alkalinization agent, for use in treatment or remission of cancer, or prevention of recurrence or metastasis of cancer.

Abstract: The present invention aims at providing novel means for administering Venetoclax, wherein the means reduces the burden on a patient caused by taking Venetoclax and achieves a good balance between the effect and safety of Venetoclax. The present invention relates to a water-soluble macromolecular derivative that includes a plurality of Venetoclaxs, each Venetoclax being linked to a terminal carboxyl group of a multi-arm water-soluble polymer via an amide bond.

Abstract: An object of the present invention is to provide a new means for treating or ameliorating a blood cancer patient, wherein the new means has high effect and few side effects. The present invention relates to a combined medicine for use in a method for treating or ameliorating a blood cancer patient, comprising 4-amino-1-(2-cyano-2-deoxy-?-D-arabinofuranosyl)-2(1H)-pyrimidinone or a salt thereof and venetoclax or a salt thereof.

Abstract: An object of the present invention is to provide a method for stabilizing a substance DFP-11207 sensitive to humidity and unstable at high humidity, and a stabilized preparation thereof, and more specifically, provide a capsule preparation for treating cancer, containing DFP-11207 or a pharmaceutically acceptable salt thereof and a hygroscopic agent.

Abstract: The present invention relates to a pharmaceutical composition comprising a citrate salt for use in enhancing the effect of an anticancer drug.

Abstract: The present invention aims at providing novel means for administering Venetoclax, wherein the means reduces the burden on a patient caused by taking Venetoclax and achieves a good balance between the effect and safety of Venetoclax. The present invention relates to a water-soluble macromolecular derivative that includes a plurality of Venetoclaxs, each Venetoclax being linked to a terminal carboxyl group of a multi-arm water-soluble polymer via an amide bond.

Abstract: The present invention relates to a pharmaceutical composition comprising a citrate salt for use in enhancing the effect of an anticancer drug.

Abstract: An object of the present invention is to provide a highly effective method for treatment/remission of cancer, and prevention of recurrence/metastasis of cancer at low cost and with few side effects. A composition containing a urinary alkalinization agent, for use in treatment or remission of cancer, or prevention of recurrence or metastasis of cancer.

Abstract: Provided is a new therapeutic agent for a malignant tumor, which is highly safe, sustains an antitumor effect, and can improve the means for administration and the number of times of administration. Disclosed is a compound of Formula (1), or a salt thereof: C[CH2O(CH2CH2O)mCH2CO—R1—R2]4??(1) wherein R1 represents a single bond, —N(R3)(CH2)n1CO—, or —N(R4)(CH2)n2N (R5)CO(CH2)n3CO—; R2 represents a group of Formula (a), (b), (c), (d), (e), or (f): m represents a number of from 10 to 1,000; and an arrow represents a bonding site.

Abstract: An object of this invention is to provide a novel delivery means that enables efficient delivery of an active ingredient to a target cell. Such objective is attained by a lipoplex comprising dioleylphosphatidylethanolamine (DOPE), phosphatidylcholine, a cationic lipid, and an RNAi molecule and an industrial method for producing the same.

Abstract: Provided is a new therapeutic agent for a malignant tumor, which is highly safe, sustains an antitumor effect, and can improve the means for administration and the number of times of administration. Disclosed is a compound of Formula (1), or a salt thereof: C[CH2O(CH2CH2O)nCH2CO—R1—R2]4 ??(1) wherein R1 represents a single bond, —N(R3)(CH2)n1CO—, or —N(R4)(CH2)n2N (R5)CO(CH2)n3CO—; R2 represents a group of Formula (a), (b), (c), (d), (e), or (f): m represents a number of from 10 to 1,000; and an arrow represents a bonding site.

Abstract: An object of this invention is to provide a novel delivery means that enables efficient delivery of an active ingredient to a target cell. Such objective is attained by a lipoplex comprising dioleylphosphatidylethanolamine (DOPE), phosphatidylcholine, a cationic lipid, and an RNAi molecule and an industrial method for producing the same.

Abstract: The present invention provides a taurine-type compound of the formula ##STR1## wherein R is a phenyl group optionally having substituent(s) selected from lower alkyl, halogen-substituted lower alkyl, lower alkoxy, lower alkanoyl and halogen atom; and n is 2 or 3. The above compound is useful as an agent for improving microcirculation.

Abstract: Disclosed is an iron-5,10,15,20-tetra(.alpha., .alpha., .alpha., .alpha.-o-substituted phenyl)porphine complex having one or four substituents with a phosphocholine group at the terminal end thereof. The substituents are positioned ortho of the phenyl group or groups.